Christopher Bouton was appointed CTO of Certara to advance AI drug discovery, following Certara's acquisition of Vyasa in 2022.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Christopher Bouton was appointed CTO of Certara to advance AI drug discovery, following Certara's acquisition of Vyasa in 2022.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Certara (United States)
company in St Louis, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireCertara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform Strengthening technology innovation and leadership of the Certara AI/ML-e